Steven Patterson of Imperial College in London will develop a new vaccine strategy that exploits the property of a protein, retinaldehyde dehydrogenase (RALDH), that stimulates immune cells to travel to the gut mucosa and there provide localized immune protection against inhabiting pathogens such as HIV. Using vaccines to generate immune responses specifically at mucosal surfaces such as in the gut or lungs, which are major sites of pathogen entry, is challenging, particularly when the vaccine must be administered with a needle, which delivers it to non-mucosal sites. They will engineer adenoviral vectors to transfer the RALDH gene to dendritic cells, and test whether these cells can then produce the relevant molecules that stimulate T and B cells to home to the gut.
Grant ID
OPP1149548
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
100000.00
Funding Currency
USD
Funding Amount (in USD)
100000.00
Project Type
Project Primary Sector
Funding Date Range
-
Funding Total (In US dollars)
100000.00
Co-Funded
False